Amycretin and Zepbound represent two ends of the weight-loss drug timeline. Amycretin, an investigational drug from the maker of Wegovy, has shown striking early results (up to about 22% to 24% weight loss) and comes in both injectable and oral forms, but it isn’t approved or available. Zepbound (tirzepatide) is FDA-approved, widely used, produces up to roughly 21% weight loss, and can be prescribed today, including through TrimRx. Here’s how they compare and why one is a real option now.<\/p>\n
Amycretin is a single molecule that activates two appetite-regulating pathways, GLP-1 and amylin, at once. That dual action is the reason for its early buzz, and Novo Nordisk is developing it in two versions: a weekly injection and a daily pill. It’s an ambitious design, but it’s still early in testing.<\/p>\n
Zepbound is tirzepatide, a dual GLP-1 and GIP agonist given as a weekly injection. It has years of trial data behind it, an FDA approval for obesity (and separately for sleep apnea), and a large real-world track record. Where amycretin is a promising unknown, Zepbound is a known quantity.<\/p>\n
Amycretin’s early numbers are what drew attention. In a phase 1b\/2a trial<\/a> published in The Lancet in 2025, injectable amycretin produced roughly 22% weight loss over 36 weeks, with the oral version showing around 13% over a shorter period. Zepbound, in its SURMOUNT trials, produced up to about 21% weight loss. The catch is that amycretin’s figures come from small, early studies, while Zepbound’s come from large, completed trials.<\/p>\n The most important difference is not the numbers, it’s availability. Amycretin only entered phase 3 trials in early 2026, and even in the best case, approval is likely years away, with some estimates pointing to around 2030. Its early results are promising, but early results sometimes shrink in larger trials, so they should be read with caution.<\/p>\n Zepbound, by contrast, is here. It’s approved, its safety and results are well documented, and TrimRx prescribes tirzepatide in both compounded and brand-name forms. For someone who wants effective treatment now rather than a promising maybe, that difference is decisive.<\/p>\n Consider a hypothetical patient excited by amycretin’s early numbers and wondering whether to wait for it. Given the long runway ahead, waiting means staying untreated for years, while Zepbound could deliver comparable weight loss starting now. You can see how to get started on the TrimRx homepage<\/a> or by taking the quiz<\/a>.<\/p>\n Amycretin’s early trials showed weight loss in a similar or slightly higher range than Zepbound, but those results come from small, early studies and could change in larger trials. Zepbound has large, completed trials and is available now, while amycretin is not.<\/p>\n Amycretin entered phase 3 testing in early 2026, and approval is likely years away, with some projections around 2030. It is investigational and cannot be prescribed today.<\/p>\n Yes. TrimRx prescribes tirzepatide (the drug in Zepbound) in both compounded and brand-name forms, after a licensed provider reviews your health profile.<\/p>\n\n\n
\n \nFeature<\/th>\n Amycretin<\/th>\n Zepbound (tirzepatide)<\/th>\n<\/tr>\n<\/thead>\n \n Mechanism<\/td>\n GLP-1 and amylin (single molecule)<\/td>\n GLP-1 and GIP<\/td>\n<\/tr>\n \n Form<\/td>\n Injectable and oral (in development)<\/td>\n Weekly injection<\/td>\n<\/tr>\n \n Weight loss<\/td>\n Up to ~22% to 24% (early data)<\/td>\n Up to ~21%<\/td>\n<\/tr>\n \n Status<\/td>\n Investigational, phase 3 started 2026<\/td>\n FDA-approved<\/td>\n<\/tr>\n \n Availability<\/td>\n Not available<\/td>\n Available now, including through TrimRx<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Why One Is a Real Choice Today<\/h3>\n
Frequently Asked Questions<\/h3>\n
Is amycretin better than Zepbound?<\/h4>\n
When will amycretin be available?<\/h4>\n
Can I get Zepbound through TrimRx?<\/h4>\n